48,436
edits
Difference between revisions of "Serous carcinoma of the ovary"
Jump to navigation
Jump to search
→IHC
(→IHC) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 40: | Line 40: | ||
Precursors lesions: | Precursors lesions: | ||
*[[Serous borderline tumour]]s for low-grade serious carcinoma. | *[[Serous borderline tumour]]s for low-grade serious carcinoma. | ||
**Generally do not progress to high-grade serous carcinoma.{{fact}} | |||
*[[Serous tubal intraepithelial carcinoma]] (STIC)<ref name=pmid23240669>{{Cite journal | last1 = Vang | first1 = R. | last2 = Shih | first2 = IeM. | last3 = Kurman | first3 = RJ. | title = Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. | journal = Histopathology | volume = 62 | issue = 1 | pages = 44-58 | month = Jan | year = 2013 | doi = 10.1111/his.12046 | PMID = 23240669 }}</ref> for high-grade serous carcinoma. | *[[Serous tubal intraepithelial carcinoma]] (STIC)<ref name=pmid23240669>{{Cite journal | last1 = Vang | first1 = R. | last2 = Shih | first2 = IeM. | last3 = Kurman | first3 = RJ. | title = Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. | journal = Histopathology | volume = 62 | issue = 1 | pages = 44-58 | month = Jan | year = 2013 | doi = 10.1111/his.12046 | PMID = 23240669 }}</ref> for high-grade serous carcinoma. | ||
| Line 106: | Line 107: | ||
==IHC== | ==IHC== | ||
*WT-1 +ve - '''key immunostain'''.<ref name=pmid18830127>{{Cite journal | last1 = Köbel | first1 = M. | last2 = Kalloger | first2 = SE. | last3 = Carrick | first3 = J. | last4 = Huntsman | first4 = D. | last5 = Asad | first5 = H. | last6 = Oliva | first6 = E. | last7 = Ewanowich | first7 = CA. | last8 = Soslow | first8 = RA. | last9 = Gilks | first9 = CB. | title = A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. | journal = Am J Surg Pathol | volume = 33 | issue = 1 | pages = 14-21 | month = Jan | year = 2009 | doi = 10.1097/PAS.0b013e3181788546 | PMID = 18830127 }}</ref> | *[[WT-1]] +ve - '''key immunostain'''.<ref name=pmid18830127>{{Cite journal | last1 = Köbel | first1 = M. | last2 = Kalloger | first2 = SE. | last3 = Carrick | first3 = J. | last4 = Huntsman | first4 = D. | last5 = Asad | first5 = H. | last6 = Oliva | first6 = E. | last7 = Ewanowich | first7 = CA. | last8 = Soslow | first8 = RA. | last9 = Gilks | first9 = CB. | title = A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. | journal = Am J Surg Pathol | volume = 33 | issue = 1 | pages = 14-21 | month = Jan | year = 2009 | doi = 10.1097/PAS.0b013e3181788546 | PMID = 18830127 }}</ref> | ||
*CK7 +ve. | *[[CK7]] +ve. | ||
*CA-125 +ve. | *CA-125 +ve. | ||
*ER +ve.<ref name=pmid21164285>{{Cite journal | last1 = DeLair | first1 = D. | last2 = Oliva | first2 = E. | last3 = Köbel | first3 = M. | last4 = Macias | first4 = A. | last5 = Gilks | first5 = CB. | last6 = Soslow | first6 = RA. | title = Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. | journal = Am J Surg Pathol | volume = 35 | issue = 1 | pages = 36-44 | month = Jan | year = 2011 | doi = 10.1097/PAS.0b013e3181ff400e | PMID = 21164285 }}</ref> | *ER +ve.<ref name=pmid21164285>{{Cite journal | last1 = DeLair | first1 = D. | last2 = Oliva | first2 = E. | last3 = Köbel | first3 = M. | last4 = Macias | first4 = A. | last5 = Gilks | first5 = CB. | last6 = Soslow | first6 = RA. | title = Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. | journal = Am J Surg Pathol | volume = 35 | issue = 1 | pages = 36-44 | month = Jan | year = 2011 | doi = 10.1097/PAS.0b013e3181ff400e | PMID = 21164285 }}</ref> | ||
| Line 143: | Line 144: | ||
Clinical and radiologic correlation is suggested for the determination of | Clinical and radiologic correlation is suggested for the determination of | ||
the primary site of this serous carcinoma. | the primary site of this serous carcinoma. | ||
High-grade serous carcinoma of ovary/fallopian tube/periteonum is associated | |||
with BRCA1/2 mutation in approximately 20% of patients. Referral to genetic | |||
counseling is recommended. | |||
</pre> | </pre> | ||